Yehuda Handelsman to Glucagon-Like Peptide 1
This is a "connection" page, showing publications Yehuda Handelsman has written about Glucagon-Like Peptide 1.
Connection Strength
1.404
-
SGLT-2 INHIBITION ADDED TO GLP-1 AGONIST THERAPY FOR TYPE 2 DIABETES: WHAT IS THE BENEFIT? Endocr Pract. 2015 Dec; 21(12):1442-4.
Score: 0.493
-
Efficacy and safety of the once-weekly GLP-1 receptor agonist albiglutide versus sitagliptin in patients with type 2 diabetes and renal impairment: a randomized phase III study. Diabetes Care. 2014 Oct; 37(10):2723-30.
Score: 0.452
-
Treating diabetes with incretin hormones - clinical experience. Pediatr Endocrinol Rev. 2008 Jun; 5(4):897-903.
Score: 0.295
-
A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON). Diabetes Obes Metab. 2014 Jul; 16(7):636-44.
Score: 0.110
-
Cardio-renal-metabolic disease in primary care setting. Diabetes Metab Res Rev. 2024 Mar; 40(3):e3755.
Score: 0.054